Chris P Conlon FRCP
Professor of Infectious Diseases
- Head of NDM Experimental Medicine
- Member of congregation
- Group Head / PI
- Consultant Physician and Unit Director
I am responsible for a mixture of clinical, teaching, research and administrative duties, including covering the 18 bed Infectious Diseases Unit at the Churchill Hospital. I collaborate with colleagues in HIV research and am currently on the trial steering committee of the RIVER study; a proof of principle trial of HDAC inhibitors and HIV vaccine use in an attempt to ‘cure’ HIV. I also run the TB service in Oxford and collaborate with Professor Derrick Crook and others using whole genome sequencing to improve diagnoses. I also have oversight of the Tropical Medicine Group and was recently invited to lecture at The First Beijing International Conference on Precision Medicine and Cancer Treatment Forum with a talk entitled “Medical Education in the 21st Century”
I am a Fellow and Tutor in Clinical Medicine at Oriel College, Oxford and regularly teach Oxford medical undergraduates in lectures and seminars, and at the bedside. In addition, I am a Principal Examiner in Medicine in Oxford and Chair of the Royal College of Physicians Joint Specialty Committee for Infectious Diseases.
I was Interim Head of Department for the Nuffield Department of Medicine from May 2016 until June 2019. I have also been the Head NDM Experimental Medicine since 2014.
Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study.
Eyre DW. et al, (2020), eLife, 9
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Folegatti PM. et al, (2020), The Lancet
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients
Peng Y. et al, (2020)
Clinical and epidemiological features of COVID-19 family clusters in Beijing, China.
Song R. et al, (2020), The Journal of infection
Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial.
Fidler S. et al, (2020), Lancet (London, England), 395, 888 - 898